BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia
BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.
Related Articles
Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout
Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical…
FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC
Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Panelists discuss how patients have been receptive to the proactive management approach that effectively reduces dermatologic adverse effects, despite initial concerns about adding multiple prophylactic…
Precision Active Surveillance: Leveraging Genomic Testing and CCR Scores in Prostate Cancer Management
Daniel Kim, MD, MBA discusses how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling…
First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC
First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL
Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.
Optimizing Peritoneal Carcinomatosis Treatment Strategies
In this video, CancerNetwork® spoke with Dr. Benjamin Golas, MD, chief of Surgical Oncology and gastrointestinal oncologist at Hackensack Meridian Health, ab…
Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma
Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.
EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management
Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.
T-DXd May Be the Preferred ADC in HR+/HER2– Breast Cancer
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive breast cancer/triple-negative breast cancer in DESTINY-Breast04.